Owkin and Tribun Health have joined forces in a strategic partnership aimed at advancing the development and global implementation of Artificial Intelligence (AI) Diagnostic and Research solutions tailored for pathology departments and pharmaceutical companies.
This collaboration, which is not exclusive, will result in the incorporation of Owkin's groundbreaking AI diagnostic capabilities into Tribun Health's highly regarded software platform, CaloPix, which has earned the 'Best in KLAS' recognition. This move will significantly expand the range of AI solutions available through CaloPix.
Furthermore, this partnership will allow Owkin's customers and users to leverage the benefits of Tribun Health's fully integrated software platform, EyeDo, designed to streamline the workflows associated with pathology data research.
EyeDo is the successor to the Keen Eye acquisition completed in 2022, further enhancing the capabilities of both organisations in the realm of AI-driven diagnostics and research solutions.
Click here to read the original news story.